<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00205504</url>
  </required_header>
  <id_info>
    <org_study_id>HM4060</org_study_id>
    <nct_id>NCT00205504</nct_id>
  </id_info>
  <brief_title>Oral Contraceptives in the Metabolic Syndrome</brief_title>
  <official_title>Oral Contraceptives in the Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <brief_summary>
    <textblock>
      Oral contraceptives (OCs) are the most widely used method of reversible birth control.
      However, the long-term cardiovascular safety of the widely used low-dose OCs
      (ethinyl-estradiol &lt; 50 mcg) is still debated. Although cardiovascular events are rare in
      young women whether they use OCs or not, the risks of myocardial infarction and ischemic
      stroke are increased among users of OCs who have conventional cardiovascular risk factors
      such as use of tobacco, diabetes or hypercholesterolemia. However, the risk of cardiovascular
      events in OC users with emerging cardiovascular risk factors (such as obesity and the
      metabolic syndrome) have not been investigated. Recently, the metabolic syndrome has been
      linked with the risk of cardiovascular disease. The syndrome is a clustering of risk factors
      in a single individual, and its underlying cause may be insulin resistance. Whether the
      metabolic syndrome predicts a higher cardiovascular risk in OC users has not been studied.
      This is a critical problem because the metabolic syndrome is prevalent in 24% of adults.
      Until the cardiovascular risks in users of OC are clearly defined, the appropriate use of OC
      with the least harm would not be possible.

      The investigator's long-term goal is to understand the best way to prevent and treat
      cardiovascular disease in women. The objective of this particular project is to obtain pilot
      data on the extent to which the metabolic syndrome and obesity affects glucose metabolism and
      cardiovascular risks in women taking OCs. The researchers hypothesize that women with
      metabolic syndrome and obese women will have worsened glucose metabolism and elevated
      cardiovascular risks associated with OC use, when compared to normal weight women without the
      metabolic syndrome. Results of this study will clarify the risk factors for cardiovascular
      events in women taking OCs, and will serve as pilot data for a National Institutes of Health
      (NIH) proposal. Once the cardiovascular risk factors of OC users are understood, clinicians
      can make better informed decisions about contraceptive choices for their patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Insulin Sensitivity Associated With Oral Contraceptive (OC) Use Compared Among (1) Obese Women and (2) Lean Women</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Insulin sensitivity was assessed by frequent sampling intravenous glucose tolerance test (FSIVGTT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Lipid Profile Compared Associated With OC Use Among (1) Obese Women and (2) Lean Women</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>The lipid profile is assessed through blood sample analysis for low-density lipoprotein (LDL), Triglycerides and high-density lipoprotein (HDL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Marker Changes, High Sensitive C-reactive Protein (Hs-CRP) and Adiponectin, Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Inflammatory markers are assessed through blood analysis for C-reactive protein (hs-CRP) and adiponectin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Estrogen Metabolites (Plasma) Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Waist-to-Hip Ratio Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Waist-to-hip ratio is assessed through calculated ratio of waist and hip circumference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Marker Changes (MCP-1) Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Inflammatory marker is assessed through blood analysis for Monocyte chemotactic protein-1 (MCP-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Blood Pressure Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Body Mass Index (BMI) Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Body Mass Index is a calculation of height and weight: kg/m²</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Waist Circumference Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Marker Changes, Soluble Vascular Cell Adhesion Molecule (sVCAM) and Soluble Intercellular Adhesion Molecule (sICAM), Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>These inflammatory markers are assessed through blood analysis of Soluble Vascular Cell Adhesion Molecule (sVCAM) and soluble intercellular adhesion molecule (sICAM).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <condition>Insulin Resistance</condition>
  <condition>Obesity</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Obese women with metabolic syndrome</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese women without metabolic syndrome</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>lean women without metabolic syndrome</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ortho Tri Cyclen</intervention_name>
    <description>Ortho Tri Cyclen, one tablet daily, for 6 cycles</description>
    <arm_group_label>Obese women with metabolic syndrome</arm_group_label>
    <arm_group_label>Obese women without metabolic syndrome</arm_group_label>
    <arm_group_label>lean women without metabolic syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acceptable health based on interview, medical history, physical examination, and
             laboratory tests (comprehensive metabolic panel - SMA20, and complete blood count -
             CBC);

          2. Have not taken oral contraceptives (OCs) in the past 3 months;

          3. Ability to comply with the requirements of the study;

          4. Ability and willingness to provide signed, witnessed informed consent. In addition,
             women with the metabolic syndrome must meet the National Cholesterol Education Program
             (NCEP) defined criteria of the metabolic syndrome, that is, having at least 3 of the 5
             factors:

               1. increased waist circumference &gt; 35 inches,

               2. hypertriglyceridemia ≥ 150 mg/dL,

               3. low high-density lipoprotein (HDL) cholesterol &lt; 50 mg/dL in women,

               4. hypertension (≥ 130/≥ 85 mmHg),

               5. fasting glucose ≥ 100 mg/dL.

        Obese women with or without the metabolic syndrome should have a Body Mass Index (BMI) &gt; 30
        kg/m2 and lean women should have a Body Mass Index BMI &lt; 25 kg/m2.

        Exclusion Criteria:

          1. Diabetes mellitus by fasting glucose or a 2-hour oral glucose tolerance test (OGTT);

          2. Clinically significant pulmonary, cardiac (including but not limited to ischemic heart
             disease, stable/unstable angina, and congestive heart failure), renal, hepatic,
             cholestatic, neurologic, psychiatric, infectious, and malignant disease (other than
             melanoma skin cancer);

          3. History of thromboembolism, myocardial infarction, cerebrovascular accident, vascular
             disease, known coagulopathy, prolonged immobilization, or recent major surgery (within
             past 6 months);

          4. Systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than
             100 mmHg (mild hypertension is not an exclusion criterion);

          5. History of breast cancer, migraine headaches, or age ≥ 35 years and smoker of ≥ 20
             cigarettes/day;

          6. Use of metformin, thiazolidinediones, anti-hyperlipidemic drugs, anti-hypertensive
             drugs, glucocorticoids, or anti-androgens (spironolactone, flutamide, etc.) within 3
             months;

          7. Documented or suspected illicit drug abuse or alcoholism within one year;

          8. Ingestion of any investigational drugs within 3 months prior to the study onset; and

          9. Pregnancy or lactation (≤ 6 weeks postpartum);

         10. Hematocrit &lt; 33g/dL. These exclusion criteria are based on study requirements and also
             go beyond guidelines for OC use published by the World Health Organization.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai I Cheang, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John E Nestler, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University General Clinical Research Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cheang KI, Essah PA, Sharma S, Wickham EP 3rd, Nestler JE. Divergent effects of a combined hormonal oral contraceptive on insulin sensitivity in lean versus obese women. Fertil Steril. 2011 Aug;96(2):353-359.e1. doi: 10.1016/j.fertnstert.2011.05.039. Epub 2011 Jun 15.</citation>
    <PMID>21676394</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <results_first_submitted>January 25, 2012</results_first_submitted>
  <results_first_submitted_qc>April 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2012</results_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammatory markers, oral contraceptions, obesity, metabolic syndrome X</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Obese Women</title>
          <description>Women with Body Mass Index (BMI) &gt;30 kg/m².
Note: Only two arms were analyzed for the results. Women who were candidates for taking oral contraceptive pills and had the metabolic syndrome could not be recruited. That is because some inclusion criteria for metabolic syndrome are actually exclusion criteria for safe oral contraceptive use.</description>
        </group>
        <group group_id="P2">
          <title>Lean Women</title>
          <description>Women with Body Mass Index)BMI &lt;25 kg/m²</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Obese Women</title>
          <description>Women with Body Mass Index (BMI) &gt;30 kg/m².
Note: Only two arms were analyzed for the results. Women who were candidates for taking oral contraceptive pills and had the metabolic syndrome could not be recruited. That is because some inclusion criteria for metabolic syndrome are actually exclusion criteria for safe oral contraceptive use.</description>
        </group>
        <group group_id="B2">
          <title>Lean Women</title>
          <description>Women with Body Mass Index)BMI &lt;25 kg/m²</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.3" spread="6.9"/>
                    <measurement group_id="B2" value="21.4" spread="2.3"/>
                    <measurement group_id="B3" value="23.4" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Insulin Sensitivity Associated With Oral Contraceptive (OC) Use Compared Among (1) Obese Women and (2) Lean Women</title>
        <description>Insulin sensitivity was assessed by frequent sampling intravenous glucose tolerance test (FSIVGTT).</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Women</title>
            <description>Women with Body Mass Index (BMI) &gt;30 kg/m²</description>
          </group>
          <group group_id="O2">
            <title>Lean Women</title>
            <description>Women with Body Mass Index (BMI) &lt;25 kg/m²</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Insulin Sensitivity Associated With Oral Contraceptive (OC) Use Compared Among (1) Obese Women and (2) Lean Women</title>
          <description>Insulin sensitivity was assessed by frequent sampling intravenous glucose tolerance test (FSIVGTT).</description>
          <units>mIU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Insulin sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.36" spread="2.32"/>
                    <measurement group_id="O2" value="6.62" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months Insulin sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" spread="3.12"/>
                    <measurement group_id="O2" value="8.23" spread="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Lipid Profile Compared Associated With OC Use Among (1) Obese Women and (2) Lean Women</title>
        <description>The lipid profile is assessed through blood sample analysis for low-density lipoprotein (LDL), Triglycerides and high-density lipoprotein (HDL).</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Women</title>
            <description>Women with Body Mass Index (BMI) &gt;30 kg/m²</description>
          </group>
          <group group_id="O2">
            <title>Lean Women</title>
            <description>Women with Body Mass Index (BMI) &lt;25 kg/m²</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Lipid Profile Compared Associated With OC Use Among (1) Obese Women and (2) Lean Women</title>
          <description>The lipid profile is assessed through blood sample analysis for low-density lipoprotein (LDL), Triglycerides and high-density lipoprotein (HDL).</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" spread="18.4"/>
                    <measurement group_id="O2" value="84" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" spread="25.2"/>
                    <measurement group_id="O2" value="104" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" spread="50.3"/>
                    <measurement group_id="O2" value="72" spread="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="51.1"/>
                    <measurement group_id="O2" value="106" spread="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" spread="10.7"/>
                    <measurement group_id="O2" value="53" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="12.4"/>
                    <measurement group_id="O2" value="61" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Marker Changes, High Sensitive C-reactive Protein (Hs-CRP) and Adiponectin, Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</title>
        <description>Inflammatory markers are assessed through blood analysis for C-reactive protein (hs-CRP) and adiponectin.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Women</title>
            <description>Women with Body Mass Index (BMI) &gt;30 kg/m²</description>
          </group>
          <group group_id="O2">
            <title>Lean Women</title>
            <description>Women with Body Mass Index (BMI) &lt;25 kg/m²</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Marker Changes, High Sensitive C-reactive Protein (Hs-CRP) and Adiponectin, Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</title>
          <description>Inflammatory markers are assessed through blood analysis for C-reactive protein (hs-CRP) and adiponectin.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Hs-CRP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4908.76" spread="5215.07"/>
                    <measurement group_id="O2" value="2050.77" spread="4748.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months Hs-CRP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6207.76" spread="4566.8"/>
                    <measurement group_id="O2" value="2266.02" spread="3443.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Adiponectin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17568.86" spread="5680.86"/>
                    <measurement group_id="O2" value="21976.53" spread="8322.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months Adiponectin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18408.43" spread="4934.39"/>
                    <measurement group_id="O2" value="22221.36" spread="11160.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Estrogen Metabolites (Plasma) Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</title>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Women</title>
            <description>Women with Body Mass Index (BMI) &gt;30 kg/m².
Note: Only two arms were analyzed for the results. Women who were candidates for taking oral contraceptive pills and had the metabolic syndrome could not be recruited. That is because some inclusion criteria for metabolic syndrome are actually exclusion criteria for safe oral contraceptive use.</description>
          </group>
          <group group_id="O2">
            <title>Lean Women</title>
            <description>Women with Body Mass Index)BMI &lt;25 kg/m²</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Estrogen Metabolites (Plasma) Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 16aE1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314.76" spread="179.73"/>
                    <measurement group_id="O2" value="317.47" spread="159.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months 16aE1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421.6" spread="286.57"/>
                    <measurement group_id="O2" value="383.39" spread="452.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 2ME1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.92" spread="11.03"/>
                    <measurement group_id="O2" value="32.39" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months 2ME1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.84" spread="54.29"/>
                    <measurement group_id="O2" value="45.58" spread="23.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 4ME1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.26" spread="3.58"/>
                    <measurement group_id="O2" value="4.45" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months 4ME1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="3.29"/>
                    <measurement group_id="O2" value="7.42" spread="8.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 2ME2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="1.06"/>
                    <measurement group_id="O2" value="0.91" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months 2ME2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.11"/>
                    <measurement group_id="O2" value="1.74" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline E1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217.23" spread="170.88"/>
                    <measurement group_id="O2" value="245.99" spread="128.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months E1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315.03" spread="339.15"/>
                    <measurement group_id="O2" value="227.4" spread="271.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 4ME2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.55"/>
                    <measurement group_id="O2" value="0.59" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months 4ME2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.79"/>
                    <measurement group_id="O2" value="1.14" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline E2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.11" spread="15.61"/>
                    <measurement group_id="O2" value="36.796" spread="17.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months E2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.73" spread="117.52"/>
                    <measurement group_id="O2" value="47.32" spread="61.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 2OHE1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.07" spread="126.04"/>
                    <measurement group_id="O2" value="85.62" spread="48.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months 2OHE1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.95" spread="220.24"/>
                    <measurement group_id="O2" value="57.96" spread="70.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 2OHE2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.81" spread="5.85"/>
                    <measurement group_id="O2" value="8.01" spread="3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months 2OHE2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.55" spread="21.74"/>
                    <measurement group_id="O2" value="6.05" spread="4.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 4OHE1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.78" spread="16.52"/>
                    <measurement group_id="O2" value="33.98" spread="25.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months 4OHE1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.29" spread="25.65"/>
                    <measurement group_id="O2" value="29.12" spread="15.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Total plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1068" spread="472.78"/>
                    <measurement group_id="O2" value="1022.16" spread="295.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months Total plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1342.21" spread="1166.36"/>
                    <measurement group_id="O2" value="1007.89" spread="977.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Waist-to-Hip Ratio Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</title>
        <description>Waist-to-hip ratio is assessed through calculated ratio of waist and hip circumference.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Women</title>
            <description>Women with Body Mass Index (BMI) &gt;30 kg/m²</description>
          </group>
          <group group_id="O2">
            <title>Lean Women</title>
            <description>Women with Body Mass Index (BMI) &lt;25 kg/m²</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Waist-to-Hip Ratio Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</title>
          <description>Waist-to-hip ratio is assessed through calculated ratio of waist and hip circumference.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Waist-Hip Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.059"/>
                    <measurement group_id="O2" value="0.73" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months Waist-Hip Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.057"/>
                    <measurement group_id="O2" value="0.73" spread="0.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Marker Changes (MCP-1) Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</title>
        <description>Inflammatory marker is assessed through blood analysis for Monocyte chemotactic protein-1 (MCP-1).</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Women</title>
            <description>Women with BMI &gt;30 kg/m²</description>
          </group>
          <group group_id="O2">
            <title>Lean Women</title>
            <description>Women with BMI &gt;25 kg/m²</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Marker Changes (MCP-1) Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</title>
          <description>Inflammatory marker is assessed through blood analysis for Monocyte chemotactic protein-1 (MCP-1).</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline MCP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209.56" spread="125.92"/>
                    <measurement group_id="O2" value="156.14" spread="36.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months MCP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.86" spread="159.85"/>
                    <measurement group_id="O2" value="206.66" spread="76.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Blood Pressure Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</title>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Women</title>
            <description>Women with Body Mass Index (BMI) &gt;30 kg/m².
Note: Only two arms were analyzed for the results. Women who were candidates for taking oral contraceptive pills and had the metabolic syndrome could not be recruited. That is because some inclusion criteria for metabolic syndrome are actually exclusion criteria for safe oral contraceptive use.</description>
          </group>
          <group group_id="O2">
            <title>Lean Women</title>
            <description>Women with Body Mass Index)BMI &lt;25 kg/m²</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Blood Pressure Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.1" spread="3.2"/>
                    <measurement group_id="O2" value="105.7" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.5" spread="11.7"/>
                    <measurement group_id="O2" value="106.5" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" spread="1.8"/>
                    <measurement group_id="O2" value="68.0" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4" spread="6.6"/>
                    <measurement group_id="O2" value="66.5" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Body Mass Index (BMI) Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</title>
        <description>Body Mass Index is a calculation of height and weight: kg/m²</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Women</title>
            <description>Women with Body Mass Index (BMI) &gt;30 kg/m²</description>
          </group>
          <group group_id="O2">
            <title>Lean Women</title>
            <description>Women with Body Mass Index (BMI) &lt;25 kg/m²</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Body Mass Index (BMI) Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</title>
          <description>Body Mass Index is a calculation of height and weight: kg/m²</description>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline BMI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" spread="6.7"/>
                    <measurement group_id="O2" value="21.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months BMI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" spread="4.7"/>
                    <measurement group_id="O2" value="21.4" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Waist Circumference Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</title>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Women</title>
            <description>Women with Body Mass Index (BMI) &gt;30 kg/m²</description>
          </group>
          <group group_id="O2">
            <title>Lean Women</title>
            <description>Women with Body Mass Index (BMI) &lt;25 kg/m²</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Waist Circumference Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Waist circumference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" spread="14.4"/>
                    <measurement group_id="O2" value="70.2" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months Waist circumference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.0" spread="10.5"/>
                    <measurement group_id="O2" value="70.9" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Marker Changes, Soluble Vascular Cell Adhesion Molecule (sVCAM) and Soluble Intercellular Adhesion Molecule (sICAM), Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</title>
        <description>These inflammatory markers are assessed through blood analysis of Soluble Vascular Cell Adhesion Molecule (sVCAM) and soluble intercellular adhesion molecule (sICAM).</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Women</title>
            <description>Women with Body Mass Index (BMI) &gt;30 kg/m²</description>
          </group>
          <group group_id="O2">
            <title>Lean Women</title>
            <description>Women with Body Mass Index (BMI) &lt;25 kg/m²</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Marker Changes, Soluble Vascular Cell Adhesion Molecule (sVCAM) and Soluble Intercellular Adhesion Molecule (sICAM), Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women</title>
          <description>These inflammatory markers are assessed through blood analysis of Soluble Vascular Cell Adhesion Molecule (sVCAM) and soluble intercellular adhesion molecule (sICAM).</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline sVCAM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="905" spread="190.63"/>
                    <measurement group_id="O2" value="1139.6" spread="159.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months sVCAM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="880.14" spread="180.08"/>
                    <measurement group_id="O2" value="1003.29" spread="256.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline sICAM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.34" spread="50.44"/>
                    <measurement group_id="O2" value="182.11" spread="91.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months sICAM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.2" spread="27.71"/>
                    <measurement group_id="O2" value="160.21" spread="74.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Obese Women</title>
          <description>Women with Body Mass Index (BMI) &gt;30 kg/m².
Note: Only two arms were analyzed for the results. Women who were candidates for taking oral contraceptive pills and had the metabolic syndrome could not be recruited. That is because some inclusion criteria for metabolic syndrome are actually exclusion criteria for safe oral contraceptive use.</description>
        </group>
        <group group_id="E2">
          <title>Lean Women</title>
          <description>Women with Body Mass Index)BMI &lt;25 kg/m²</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gallstones removal</sub_title>
                <description>Subject had gallstones removed during study, and continued study.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tiredness</sub_title>
                <description>Subject felt tired during her last day of study and did not desire to continue that morning's study procedure.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain with venipuncture</sub_title>
                <description>Subject withdrew withdrew after the first two mornings of study because of pain associated with venipuncture.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Phlebitis due to catheter insertion</sub_title>
                <description>Subject experienced phlebitis at the site of catheter insertion. Subject was discontinued from the study by investigator.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dizziness due to Ortho Tricyclen</sub_title>
                <description>Subject withdrew after 1 day of study medication (Ortho Tricyclen)due to dizziness.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kai Cheang, Principal Investigator</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-828-9698</phone>
      <email>kicheang@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

